420
Participants
Start Date
March 28, 2020
Primary Completion Date
July 31, 2020
Study Completion Date
September 2, 2020
Sarilumab SAR153191
Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Placebo
Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Investigational Site Number 0320001, Caba
Investigational Site Number 3800006, Rozzano
Investigational Site Number 3800005, Milan
Investigational Site Number 3800001, Milan
Investigational Site Number 3800002, Milan
Investigational Site Number 7240002, Madrid
Investigational Site Number 7240005, Madrid
Investigational Site Number 7240001, Madrid
Investigational Site Number 2500001, Bordeaux
Investigational Site Number 3800003, Modena
Investigational Site Number 3800004, Parma
Investigational Site Number 2500002, Nantes
Investigational Site Number 2760002, Essen
Investigational Site Number 2760001, Münster
Investigational Site Number 2760004, Cologne
Investigational Site Number 3760001, Ramat Gan
Investigational Site Number 2500003, Strasbourg
Investigational Site Number 2500005, Paris
Investigational Site Number 2500006, La Roche-sur-Yon
Investigational Site Number 3760002, Jerusalem
Investigational Site Number 2500007, Clamart
Investigational Site Number 2500004, Suresnes
Investigational Site Number 6430003, Moscow
Investigational Site Number 6430002, Moscow
Investigational Site Number 6430001, Moscow
Investigational Site Number 1520001, Talca
Investigational site number 3760003, Ashdod
Investigational Site Number 1520002, Santiago
Investigational Site Number 0320003, Caba
Investigational Site Number 0320004, Caba
Investigational Site Number 0760003, Porto Alegre
Investigational Site Number 0760004, São José do Rio Preto
Investigational Site Number 0760001, São Paulo
Investigational Site Number 0760002, São Paulo
Investigational Site Number 0760005, São Paulo
Investigational Site Number 1240001, Montreal
Investigational Site Number 1240005, Montreal
Investigational Site Number 1240004, Toronto
Investigational Site Number 1240002, Toronto
Investigational Site Number 1240003, Vancouver
Investigational Site Number 1520003, Santiago
Investigational Site Number 1520004, Santiago
Investigational Site Number 3920002, Fuchu-Shi
Investigational Site Number 3920003, Iruma-Gun
Investigational Site Number 3920001, Kamakura-Shi
Investigational Site Number 7240003, Barcelona
Investigational Site Number 7240004, Barcelona
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY